The FDA should back off of 23andMe and allow the firm to continue selling its consumer genomics service because it is unlikely to lead to unnecessary diagnostic tests and medical procedures, argues Forbes writer Frida Polli.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.